Omeros Achieves Profitability as Strategic Moves Slash Debt

Omeros posts $86.5M profit, slashes debt to $88M after $240M asset sale to Novo Nordisk. New drug YARTEMLEA launches successfully, with $1.8B in future milestones.

A landmark transaction with a global pharmaceutical leader and the successful launch of a new therapy have fundamentally reshaped the financial trajectory of Omeros Corporation. The biotechnology firm has not only entered profitable territory but has also made significant strides in strengthening its balance sheet, cutting its debt burden nearly in half and moving closer to sustainable financial independence.

Commercial Launch and Financial Health

The company’s financial turnaround was cemented in the fourth quarter of 2025. A pivotal asset sale to Novo Nordisk, involving the rights to zaltenibart, provided an immediate cash infusion of $240 million. This transaction was transformative, swinging the company from a net loss of $31.4 million in the prior year to a net profit of $86.5 million.

Management deployed a substantial portion of these proceeds to reduce outstanding obligations. As a result, total debt plummeted by 47 percent year-over-year to approximately $88 million. This strategic deleveraging leaves Omeros in a robust liquidity position, with cash and equivalents of $171.8 million on hand as of December 31, 2025.

Concurrently, Omeros has commenced the U.S. commercialization of YARTEMLEA, a treatment for a rare complication following stem cell transplants. Since its January 2026 launch, adoption has been rapid. Nearly half of the nation’s ten leading transplantation centers have already incorporated the drug into their treatment protocols. Company leadership projects that this new business unit will achieve financial self-sufficiency within the current year.

Future Revenue Catalysts and Pipeline

The partnership with Novo Nordisk extends far beyond the initial payment, embedding significant potential value for Omeros’ future. The agreement structures substantial additional payments contingent on achieving specific clinical, regulatory, and commercial milestones:

• $100 million for near-term development targets
• $410 million tied to development and regulatory achievements
• $1.3 billion in commercial milestones based on sales performance

A key near-term catalyst is an anticipated regulatory decision from the European Medicines Agency (EMA) in mid-2026. A positive opinion would substantially expand the addressable market for YARTEMLEA and trigger further licensing revenue.

While the company targets positive cash flow by 2027, it acknowledges that increased marketing and sales expenditures to support the product launch will likely pressure earnings in early 2026. However, the strong current cash position provides ample runway to fund these commercial efforts while continuing to advance the rest of its development pipeline, including the investigational drug OMS1029.